Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Interstitial Lung Disease Therapy
Investigators at Yale University release new data on interstitial lung disease therapy
November 9th, 2008
Data detailed in 'Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports' have been presented. According to a study from the United States, "To systematically review all published case reports and the US Food and Drug Administration adverse event reporting (FDA-AER) database to examine the relationship between statins and interstitial lung disease (ILD). PubMed (1987 to September 2007) and the FDA-AER database (as of June 2007) were searched for reports of ILD in which a statin was listed as a causative suspect." "REVIEW METHODS: Two authors (one author for Pub Med cases and one for FDA-AER...
Source: Medical Letter on the CDC & FDA (2008-11-09)
|
